文献速递神经肿瘤

大脑胶质瘤病的治疗模式与生存模式:基于SEER数据库的分析

Management and Survival Patterns of Patients with Gliomatosis Cerebri: A SEER-Based Analysis.
PubMed 文献 · World Neurosurg · 2017-03-30

研究利用SEER数据库(1999-2010)分析111例成年大脑胶质瘤病(GC)患者的临床实践模式与总生存。58%获得显微镜确诊;放疗与手术均与生存无关,仅诊断年龄与总生存显著相关;>50岁患者在替莫唑胺时代(2005-2010)生存优于前替莫唑胺时代(1999-2004)。作者提出应对GC患者进行组织学确诊。

要点

  • 111例GC患者中58%获得显微镜确诊,未确诊者中7%接受了放疗。
  • 放疗与手术均与生存无关,仅诊断年龄与总生存显著相关。
  • 18-50岁患者中位生存11个月,>50岁患者6个月(P=0.03)。

核心结论

  • 在SEER数据库中,约40%影像学表现为GC的胶质瘤患者未获得显微镜确诊。
  • 作者提出,对GC患者进行组织学确诊是合理的,因为对标本做基因组分析可能为有意义的治疗干预提供线索。

研究设计与样本

  • 基于SEER数据库(1999-2010)的分析,纳入111例年龄≥18岁、临床或显微镜诊断的大脑中胶质瘤病(GC)患者,GC定义为累及大脑3个或以上脑叶的胶质瘤。
  • 分析这些患者的临床实践模式,以及这些实践是否与生存相关。

主要发现

  • 111例GC患者中58%获得显微镜确诊;其余患者中40%通过影像学或实验室检查诊断,2%诊断方法未知。
  • 未获得显微镜确诊的患者中7%接受了放疗。
  • 放疗和手术均与生存无关。
  • 唯一与总生存显著相关的变量是诊断年龄:18-50岁患者较>50岁患者生存改善(中位生存分别为11个月和6个月;P=0.03)。
  • >50岁患者中,替莫唑胺时代后(2005-2010)较替莫唑胺时代前(1999-2004)总生存改善(中位生存分别为9个月和4个月;P=0.005)。

关键数值与推荐

  • GC定义为累及大脑3个或以上脑叶的胶质瘤。
  • 18-50岁患者中位生存11个月,>50岁患者中位生存6个月(P=0.03)。
  • >50岁患者中,2005-2010年中位生存9个月,1999-2004年中位生存4个月(P=0.005)。

临床怎么用

  • 作者提出,对GC患者进行组织学确诊是合理的,因为对标本做基因组分析可能为有意义的治疗干预提供线索。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We used the SEER (Surveillance Epidemiology and End Results) database (1999-2010) to analyze the clinical practice patterns and overall survival in patients with gliomatosis cerebri (GC), or glioma involving 3 or more lobes of the cerebrum. METHODS: We identified 111 patients (age ≥18 years) with clinically or microscopically diagnosed GC in the SEER database. Analyses were performed to determine clinical practice patterns for these patients and whether these practices were associated with survival. RESULTS: Fifty-eight percent of the 111 patients with GC received microscopic confirmation of their diagnosis. Of the remaining patients, 40% were diagnosed via imaging or laboratory tests, and 2% had unknown methods of diagnosis. Seven percent of patients who did not have microscopic confirmation of their diagnosis received radiation therapy. Radiation therapy and surgery were not associated with survival. The only variable significantly associated with overall survival was age at diagnosis. Patients aged 18-50 years showed improved survival relative to patients aged >50 years (median survival, 11 and 6 months, respectively; P = 0.03). For patients aged >50 years, improved overall survival was observed in the post-temozolomide era (2005-2010) relative to those treated in the pre-temozolomide era (1999-2004) (median survival, 9 and 4 months, respectively; P = 0.005). CONCLUSIONS: In the SEER database, ∼40% of the patients with glioma with imaging findings of GC do not receive microscopic confirmation of their diagnosis. We propose that tissue confirmation is warranted in patients with GC, because genomic analysis of these specimens may provide insights that will contribute to meaningful therapeutic intervention.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Carroll KT, Hirshman B, Ali MA, et al. Management and Survival Patterns of Patients with Gliomatosis Cerebri: A SEER-Based Analysis. World Neurosurg. 2017. PMID: 28366748. doi:10.1016/j.wneu.2017.03.103

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。